Next, we tried to explore the prognostic impact of the SKP2 gene to predict the treatment responses at the early time point (3 months); the ROC analysis revealed that the best cut-off value of the SKP2 gene expression level that differentiated the optimal response from the warning/failure response was >2.42, yielding a sensitivity of 70.59% and a specificity of 71.21%, with an AUC of 0.815 (p < 0.001) (Figure 4), suggesting that SKP2 gene expression could be an independent prognostic marker to predict the treatment responses in the CML patients at the early time point (3 months). This evidence concerns the gene SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive.